Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.
Loreta Anesti KondiliGiovanni Battista GaetaMaurizia Rossana BrunettoAlfredo Di LeoAndrea IannoneTeresa Antonia SantantonioAdele GiammarioGiovanni RaimondoRoberto FilomiaCarmine CoppolaDaniela Caterina AmorusoPierluigi BlancBarbara Del PinLiliana ChemelloLuisa CavallettoFilomena MoriscoLaura DonnarummaMaria Grazia RumiAntonio GasbarriniMassimo SicilianoMarco MassariRomina CorsiniBarbara CocoSalvatore MadoniaMarco CannizzaroAnna Linda ZignegoMonica MontiFrancesco Paolo RussoAlberto ZanettoMarcello PersicoMario MasaroneErica VillaVeronica BernabucciGloria TalianiElisa BiliottiLuchino ChessaMaria Cristina PasettoPietro AndreoneMarzia MargottiGiuseppina BrancaccioDonatella IeluzziGuglielmo BorgiaEmanuela ZappuloVincenza CalvarusoSalvatore PettaLoredana FalzanoMaria Giovanna QuarantaLiliana Elena WeimerStefano RosatoStefano VellaEdoardo Giovanni GianniniPublished in: PloS one (2017)
Failure rate following the first DAA regimen in patients with advanced disease is similar to or lower than that reported in clinical trials, although the majority of patients were treated with suboptimal regimens. Interim findings showed that worsening of liver function after failure, in terms of Child Pugh class deterioration, was improved by successful retreatment in about one third of retreated patients within a short follow-up period; however, in some advanced liver disease patients, clinical outcomes (Child Pugh class, HCC development, liver failure and death) were independent of viral eradication.